From BioHealth Investor
by H.S. Ayoub
BioHealth Investor.com
Biotechnology
OSIRIS THERAPEUTICS [OSIR] +15.40%
REXAHN PHARMACEUTICL [RXHN.OB] +12.90%
ADVENTRX PHARMACTL [ANX] +10.05%
MEDICURE INC [MCU] +8.91%
BIONOVO INC [BNVI.OB] +8.51%
Diagnostic Substances
RG GLBL LIFESTYLS [RGBL.OB] +17.45%
SYNOVICS PHARMACEUTL [SYVC.OB] +11.20%
EPIX PHARMACEUTICALS [EPIX] +5.18%
PRESSURE BIOSCIENC [PBIO] +5.12%
EPICEPT CORPORATION [EPCT] +3.66%
Drug Delivery
BENTLEY PHARMACEUTIC [BNT] +4.91%
NEKTAR THERAPEUTIC [NKTR] +2.39%
ELAN CP PLC ADR [ELN] +1.92%
QUIGLEY CORP THE [QGLY] +1.51%
IOMED INC [IOX] +0.60%
Drug Manufacturers
ATHEROGENICS INC [AGIX] +15.84%
ADAMS RESPIRATORY TH [ARXT] +15.24%
PROVECTUS PHARMA [PVCT.OB] +14.73%
CHATTEM INC [CHTT] +8.62%
EXEGENICS INC [EXEG.OB] +7.92%
Drug Related Products
TIENS BIOTECH GR USA [TBV] +6.74%
DRAXIS HEALTH INC [DRAX] +3.15%
NATROL INC [NTOL] +1.89%
NUTRACEUTICAL INTL [NUTR] +1.40%
MANNATECH INC [MTEX] +1.36%
Generic Drugs
MYLAN LABS INC [MYL] +5.17%
CATALYST PHARMACEUTI [CPRX] +3.38%
PHARMACUTICAL CO [PRX] +1.46%
ISOLAGEN INC [ILE] +1.16%
HI-TECH PHARMACAL [HITK] +0.98%
Medical Appliances & Equipment
CAMBRIDGE HEART INC [CAMH.OB] +18.08%
THERAGENICS CORP [TGX] +14.85%
IVIVI TECHNOLOGIES, [II] +10.39%
SRI/SURGICAL EXPRE [STRC] +8.48%
NON INVASIVE MONITORNG SYS NEW [NIMU.OB] +7.14%
Medical Instruments & Supplies
CARDIOTECH INTL [CTE] +20.03%
OCULUS INNOVATIVE SC [OCLS] +14.90%
BIOFORCE NANOSCIENCE [BFNH.OB] +7.69%
INOVIO BIOMED CORP [INO] +6.67%
CPC OF AMERICA INC [CPCF.OB] +5.26%
Medical Laboratories & Research
AETERNA ZENTARIS [AEZS] +7.93%
MEDASORB TECHNOLOGS [MSBT.OB] +4.55%
ENZO BIOCHEM INC [ENZ] +3.77%
ALLIANCE IMAGING INC [AIQ] +3.47%
SPHERIX INC [SPEX] +3.43%
http://www.biohealthinvestor.com/
Buffett Missed These Two…
Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.
But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.
Unlock the two dividend legends Buffett missed in this new free report.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.